Subscribe to Newsletter

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Content by Michael Schubert:

Subspecialties Retina

Automated AMD Assistance

| Michael Schubert

Could a new image analysis technique contribute to earlier or more accurate diagnosis of AMD?

Subspecialties Cataract

Accommodating Accommodating IOLs

| Michael Schubert

Patients with myopia often get poorer results from accommodating IOLs than those without – and a recent study explains why

Subspecialties Basic & Translational Research

RGCs from the FACS machine

| Michael Schubert, Mark Hillen

For retina stem cell researchers, growing and purifying lots of RGCs from hPSCs has been hard… until now

Subspecialties Basic & Translational Research

Drugs From the Deep

| Michael Schubert

Marine mammals have tear films filled with interesting antimicrobial agents – and understanding the compounds present might one day lead to new antibiotic drugs

Subspecialties Neuro-ophthalmology

The Nature of Neuromyelitis Optica

| Michael Schubert

A retrospective study by the Neuromyelitis Optica Study Group helps physicians better understand the challenging disease

Subspecialties Cornea / Ocular Surface

ATOM2: Low-dose Atropine Attenuates Myopia

| Michael Schubert

5-year ATOM2 trial data confirms that 0.01% atropine is more effective at slowing myopia progression than 0.1% and 0.5% doses

Subspecialties Cornea / Ocular Surface

Dodging the Downsides of Corneal Epithelium Debridement

| Michael Schubert

A new matrix therapy agent may promote corneal healing after epi-off CXL, improving patient comfort and recovery times

Business & Profession Professional Development

Business In Brief

| Michael Schubert

Glaukos submits iDose IND to the FDA, Allergan bimatoprost implant shows promise, and ALPHAEON makes three deals in as many weeks

Subspecialties Retina

What’s Old is New (II)

| Michael Schubert

Placental growth factor inhibitors might show efficacy in treating dry AMD as well as wet. Might aflibercept be repurposed?

Business & Profession Professional Development

A Turbulent Transaction?

| Michael Schubert

Pfizer and Allergan are to combine to form the world’s biggest pharma company, an eyecare behemoth – with a lower tax bill

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: